Biopsychological and biomedical effect of cannabinoidAn efficient new cannabinoid antiemetic in pediatric oncology
References (28)
- et al.
Pharmacol Biochem Behav
(1991) - et al.
Eur J Pharmacol.
(1989) - et al.
Tetrahedron
(1966) - et al.
Blood
(1984) Pharmac. Ther.
(1988)- et al.
- et al.
Toxicol. Appl. Pharmacol.
(1973) - et al.
Toxicol Appl Pharmacol.
(1973) - et al.
J Am Chem Soc.
(1964)
N Engl J Med.
(1975)
Pharmacol Revs.
(1986)
Drugs
(1993)
Cited by (156)
Assessment of dependence potential and abuse liability of Δ<sup>8</sup>-tetrahydrocannabinol in mice
2022, Drug and Alcohol DependenceCitation Excerpt :For example, Δ8-THC is a quasilegal minor cannabinoid with antiemetic effects and structural stability. Early enthusiasm for clinical use of Δ8-THC was dampened by its ability to produce psychotropic effects (Abramahov et al., 1995; Hollister and Gillespie, 1972). When administered acutely, Δ8-THC produces cannabimimetic effects in male ddN, ICR, and Swiss-Webster mice, including catalepsy (Watanabe et al., 1983), antinociception, decreased locomotor activity (Compton et al., 1991; Dewey et al., 1970), and hypothermia (Ham and Jong, 1974; Yamamoto et al., 1985).
“Recent challenges and trends in forensic analysis: Δ9-THC isomers pharmacology, toxicology and analysis”
2022, Journal of Pharmaceutical and Biomedical AnalysisThe current state of delta-8 THC
2022, American Journal of Emergency MedicineCannabinoid Hyperemesis Syndrome Secondary to Delta-8 THC Use
2021, American Journal of MedicineChemistry and Pharmacology of Delta-8-Tetrahydrocannabinol
2024, Molecules
Copyright © 1995 Published by Elsevier Inc.